In about a month, Mr. Droga plans to test his theory with the trial introduction by Droga5 and its partner, the Publicis Groupe, of a Web site named honeyshed.com.
Tom Markworth, Hewlett-Packard's product marketing manager for consumer PC's, said that after his company's trial introduction of Compaq-branded gaming computers in November, "you can expect to see other gaming offerings from H-P".
But the judge, Colonel Tara Osborn, barred prosecutors from referencing Akbar, saying Akbar wasn't on trial and introduction of such material would "only open the door to a mini trial".
In (petitioner) Mackey's trial, the introduction of the wagering tax forms did not jeopardize the integrity of the trial except to the extent that they showed that he was engaged in illegal activities other than that charged.
Since Anita had not been cross-examined at the preliminary hearing and was absent at trial, the introduction of the transcript of her testimony was held to have violated respondent's confrontation [p62] right.
He pointed to a wall that offered what he called "contextual bits": mentions of the Scopes trial; the introduction, in England, of a ten-pound bank note with Darwin's likeness on it; and the briefest nod to the Dover, Pennsylvania, school-board trial, concerning intelligent design, that is winding down right now.
An initial behavioral study indicated that contextual fear conditioning can occur in a single trial when introduction to a novel context CS is followed 26 min later by delivery of footshock US.
At 3 months into the trial, the introduction of the 'open access' policy to all women regardless of initially expressed preferences resulted in an increase in patient numbers approached and recruited.
For example, in the cluster randomized trial of introduction of a new delivery system for ITNs within the context of an existing delivery system by Mueller et al [ 21], the use of a randomized control introduced unnecessary complexity.
In this sub-study of the SWAP randomized clinical trial, the introduction of fixed-dose treatment with ABC/3TC lead to increases in plasma levels of E-selectin and sVCAM-1 compared with fixed-dose treatment with TDF/FTC, but the effect was short term and could not be detected after 12 and 48 weeks of follow up.
Second, changes in the design and analysis of Phase I trials, the introduction of "targeted" investigational agents that are generally less toxic, and an increase in Phase I trials that combine two or more agents in a novel way have changed the conduct of these trials and decreased fears and apprehensions about participation.
